Literature DB >> 11121835

Pharmacological chaperones: a new twist on receptor folding.

J P Morello1, U E Petäjä-Repo, D G Bichet, M Bouvier.   

Abstract

Protein misfolding is at the root of several genetic human diseases. These diseases do not stem from mutations within the active domain of the proteins, but from mutations that disrupt their three-dimensional conformation, which leads to their intracellular retention by the quality control apparatus of the cell. Facilitating the escape of the mutant proteins from the quality control system by lowering the temperature of the cells or by adding chemicals that assist folding (chemical chaperones) can result in proteins that are fully functional despite their mutation. The discovery that ligands with pharmacological selectivity (pharmacological chaperones) can rescue the proper targeting and function of misfolded proteins, including receptors, might help to develop new treatments for 'conformational diseases'.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121835     DOI: 10.1016/s0165-6147(00)01575-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  57 in total

1.  Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

Authors:  Ulla E Petäjä-Repo; Mireille Hogue; Suparna Bhalla; André Laperrière; Jean-Pierre Morello; Michel Bouvier
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

Review 2.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.

Authors:  Marina S Gelman; Ron R Kopito
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

4.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

5.  Dimethyl sulfoxide reduces hepatocellular lipid accumulation through autophagy induction.

Authors:  Young Mi Song; Sun-Ok Song; Yong-Keun Jung; Eun-Seok Kang; Bong Soo Cha; Hyun Chul Lee; Byung-Wan Lee
Journal:  Autophagy       Date:  2012-06-22       Impact factor: 16.016

6.  In silico and in vivo models for Qatari-specific classical homocystinuria as basis for development of novel therapies.

Authors:  Hesham M Ismail; Navaneethakrishnan Krishnamoorthy; Nader Al-Dewik; Hatem Zayed; Nura A Mohamed; Valeria Di Giacomo; Sapna Gupta; Johannes Häberle; Beat Thöny; Henk J Blom; Waren D Kruger; Tawfeg Ben-Omran; Gheyath K Nasrallah
Journal:  Hum Mutat       Date:  2018-11-23       Impact factor: 4.878

7.  Transmembrane region of N-methyl-D-aspartate receptor (NMDAR) subunit is required for receptor subunit assembly.

Authors:  Jing-yuan Cao; Shuang Qiu; Jie Zhang; Jie-jie Wang; Xiao-min Zhang; Jian-hong Luo
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

8.  Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.

Authors:  Jo Ann Janovick; M David Stewart; Darla Jacob; L D Martin; Jian Min Deng; C Allison Stewart; Ying Wang; Anda Cornea; Lakshmi Chavali; Suhujey Lopez; Shoukhrat Mitalipov; Eunju Kang; Hyo-Sang Lee; Pulak R Manna; Douglas M Stocco; Richard R Behringer; P Michael Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

Review 9.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro.

Authors:  Michael J Lumb; Graeme M Birdsey; Christopher J Danpure
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.